Form 4 for XERS Xeris Biopharma Holdings, Inc.
Accepted 2026-02-02 00:00:00 ET · period of report 2026-01-30 · accession 0002058704-26-000002 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2026-02-02 | 2026-01-30 | XERS | Nguyen Anh Tu | See Remarks | A - Grant | $0.00 | +121.3K | 424.3K | +40% | $0 |
| D | 2026-02-02 | 2026-01-30 | XERS | Nguyen Anh Tu | See Remarks | A - Grant | $0.00 | +162.2K | 162.2K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-01-30 | A | A | 121,293 | $0.00 | 424,323 | D | — | — | (F1) These shares were acquired pursuant to a restricted stock unit grant under the Company's 2018 Stock Option and Incentive Plan (the "Plan"). Each restricted stock unit represents a contingent right to receive one share of the Company's common stock. These shares shall vest in equal annual installments over three years, subject to continued employment through such vesting date. (F2) Includes 3,030 shares acquired on December 31, 2025 under the issuer's 2018 Employee Stock Purchase Plan, as amended. |
| 2 | Derivative | Stock Option (Right to Buy) | 2026-01-30 | A | A | 162,162 | $0.00 | 162,162 | D | $7.36 · — to 2036-01-30 | 162,162 Common Stock | (F4) These stock options were acquired pursuant to a grant under the Plan. These stock options shall vest in equal annual installments over three years, subject to continued service through such vesting date. |